Abstract. Coumarins have attracted intense interest in recent years due to their apoptogenic effects. The aim of the present study was to determine whether 7-hydroxycoumarin (7-HC) induces changes in caspase-3 (C-3) activity in A549 human lung carcinoma cells. A range of analytical techniques, including colorimetric and fluorometric assays, western blotting, single-cell microinjection, fluorescence microscopy and image analysis were conducted to elucidate the effects of 7-HC. A 24-h exposure to 1.85 mM 7-HC induced a 65% increase in C-3 activity, and a notable conversion of procaspase-3 to C-3, in addition to poly(ADP-ribose)polymerase cleavage. Furthermore, morphological changes associated with apoptosis were observed. Exposure of the cells to 7-HC for 3 or 6 h increased calcium conductance by 27%. By performing the single-cell microinjection of a specific fluorescent substrate of C-3 into previously 7-HC-exposed cells, a typical enzymatic kinetic profile of C-3 activation was identified a number of hours prior to the morphological and biochemical changes associated with apoptosis being observed. These results suggest that the rapid in vivo activation of C-3 is induced by 7-HC, the most relevant biotransformation product of coumarin in humans.

Introduction
Lung cancer is a global public health issue. In the USA, cancer of the lung and bronchus represents 13.5% of all new cancer cases. The estimated number of new cases for 2014 in the USA is 224,210 and the estimated number of patients that will succumb to these diseases is 159,260 (1). The US National Cancer Institute defines targeted cancer therapies as drugs or other substances that interfere with specific molecules associated with cancer cell growth and survival. Targeted cancer therapies that have been approved for use include agents that prevent cell growth signaling, interfere with the development of tumor-supplying blood vessels, induce cancer cell death, stimulate the immune-mediated destruction of cancer cells and/or deliver toxic drugs to cancer cells. These therapies are frequently cytostatic, blocking tumor cell proliferation. At present, targeted therapies are the focus of copious anticancer drug development research efforts, which aim to identify of targets that are crucial to cancer cell growth and survival (2).

The US Food and Drug Administration (FDA) approved coumarin as an orphan drug for the treatment of renal cell carcinoma on December 22, 1994 (3). The name coumarin is derived from the word coumarou, an alternative name for the tonka bean (Dipteryx odorata Willd., Fabaceae). Chemically, coumarins have a benzopyrone structure. Umbelliferone, esculetin and scopoletin are the most widespread coumarins in nature (4). Coumarins have been investigated as potential treatments for various clinical conditions, such as high protein edema (5), chronic infections (6,7) and cancer (8-10). The apoptogenic properties of coumarins have attracted intense interest in recent years. The induction of apoptosis by natural (11-18) and synthetic (19-21) coumarins has been reported in human leukemia cells, lung carcinoma cell lines, adipocytes, HeLa cells, hepatocellular carcinoma, human neuroblastoma cell lines and human prostate cancer cell lines. The induction of apoptosis occurs via mitochondrial pathways, including the modulation of the NF-kB, mitogen-activated protein kinase (MAPK) and p53 pathways, which subsequently activate caspase-3 (C-3)-dependent mechanisms. The downregulation of Rho GTPases (RhoGDIα) by a coumarin derivative.
through transcriptomic and proteomic mechanisms (22) has been described. A previous study (12) observed that the A427 lung carcinoma cell line exhibited increases in the proportion of Annexin-V-positive cells of 50 and 83% compared with solvent-treated cells (estimated using flow cytometry), when exposed to 100 µg/ml coumarin and 7-hydroxycoumarin (7-HC), respectively, for 4 h.

The aim of the present study was to determine whether changes in C-3 activity are induced in a single live A549 human lung carcinoma cell by treatment with 7-HC, the primary human biotransformation product of coumarin (23), by performing the single-cell microinjection of a C-3 substrate.

Materials and methods

Reagents. A549 lung carcinoma cells (CRM-CCL-185) were obtained from American Type Culture Collection (Rockville, MD, USA). Ionomycin and RPMI-1640 medium were purchased from Gibco Life Technologies (Carlsbad, CA, USA). Fetal bovine serum (FBS) was obtained from GE Healthcare Life Sciences (Logan, UT, USA). MTT, 5-bromo-4-chloro-3-indolyl phosphate/nitro-blue tetrazolium chloride (BCIP/NBT), ethylene glycol-bis (β-aminomethyl ether)-N,N,N',N'-tetraacetic acid (EGTA) tetrasodium salt and a caspase-3 colorimetric assay kit were purchased from Sigma-Aldrich (St. Louis, MO, USA). Monoclonal anti-caspase 3 clone 4-1-18 (#MA1-16843) and monoclonal anti-α-(ADP-ribose) polymerase (PARP) clone 123 antibodies (#43600) were obtained from Zymed Laboratories, Inc. (San Francisco, CA, USA). Rhodamine 110, bis-(N-CBZ-L-aspartyl-L-glutamyl-L-valyl-L-aspartic acid amide) (Z-DEVD-R110) was purchased from Invitrogen Life Technologies (Camarillo, CA, USA). Borosilicate glass capillaries (1B100F-4) were obtained from World Precision Instruments, Ltd. (Sarasota, FL, USA). Dextran-Texas Red [3,000 molecular weight (MW)], dextran-fluorescein isothiocyanate (FITC) (3,000 MW) and Fura-2AM dyes were purchased from Molecular Probes Life Technologies (Carlsbad, CA, USA). Tissue culture flasks (80 cm²) and 6-well multidishes were obtained from Nunc A/S (Roskilde, Denmark). A 35x10-mm polystyrene dish was purchased from Corning, Inc. (New York, NY, USA).

Cell culture. A549 human lung carcinoma cells were cultured at 37°C in 5% CO₂ using RPMI-1640 medium, supplemented with a 10% heat-inactivated FBS. Cells were sub-cultured through trypsinization, seeded at 2x10⁵ cells/mL in 6-well plates or Petri dishes, and left to affix for 24 h prior to exposure to the final solvent concentration was 3%. The viability of the cell line was determined using an MTT assay (24). Cells were seeded at a density of 5x10⁵ cells/100 µl RPMI-1640 in a 96-well microplate. Cells were treated with ethanol (control) or a solution of 7-HC in ethanol (1.85 mM) for 24 h. The final concentration of ethanol was 3% (v/v). The number of viable cells was estimated by treatment with 20 µl/well MTT (5 mg/ml) for 4 h, enabling the mitochondrial succinate dehydrogenase in viable cells to reduce MTT to purple formazan crystals. The medium was aspirated and 100 µl dimethyl sulfoxide (DMSO)/well was added. Crystals were dissolved in DMSO and the absorbance at 570 nm was measured using an ELx800 microplate reader (Biotek Instruments, Inc., Winooski, VT, USA). The percentage inhibition of cell viability (%IC) was measured using the following formula: %IC = [1 - absorbance of cells treated with 7-HC in ethanol/absorbance of cells in ethanol] x 100.

Colorimetric assay to determine the time course and concentration response of C-3 activity. To evaluate the concentration response, A549 cells were exposed to ethanolic solutions of 7-HC (0.61, 1.23 or 1.85 mM) for 24 h with three replicates per concentration. In order to determine the time course, A549 cells were exposed to a 1.85-mM ethanolic solution of 7-HC for 6, 12 or 24 h. Cell lysates were obtained (as described below) and an endpoint colorimetric method based on peptide hydrolysis (Ac-DEVD-pNA) was employed (Novex Caspase 3-Caspase Colorimetric Protease Assay Kit; Thermo Fisher Scientific, Waltham, MA, USA) and the absorbance at 405 nm was measured using an ELx800 microplate reader. The mean value of the solvent-treated cell absorbance was calculated for use as a basal reference. Response-increase percentages of the different drug exposures were determined and plotted as the C-3 enzymatic activity index: Ratio of C-3 activity = [optical density (OD) treatment/OD control treatment] x 100.

Protein isolation and quantitation. Following each cell treatment, cell lysates were obtained using a lysis buffer containing 20 mM Tris, 150 mM NaCl, 1 mM NaOH, 1 mM ethylene-diaminetetraacetic acid, 1 mM EGTA and 1% Triton X-100. The protein concentration was estimated using a Micro BCA Protein assay kit (Pierce Biotechnology, Inc., Rockford, IL USA).

Concentration-response assays. In 6-well multidishes 1.5x10⁶ A549 cells were let to affix in three RPMI-1640 replicates, then exposed to 0.3, 0.6, 0.92 or 1.85 mM 7-HC for 24 h.

Time course assays. Next, 1.5x10⁶ A549 cells were triplicated, then exposed to either ethanol or 1.85 mM ethanol-dissolved 7-HC for 6, 12, 18 or 24 h. In each case the final solvent concentration was 3%. The procedure was completed as described in the protein isolation and quantitation section.

Western blot analysis. Protein expression was determined by conducting electrophoresis using a polyacrylamide gel (SDS-PAGE) at 15%. Proteins were then transferred at 25 V/300 mA to polyvinylidene fluoride membranes. Procaspe-3, C-3 and PARP expression levels were determined by incubating the membranes with primary antibodies (1.5 µg/ml) against caspase-3 (1:250) and PARP (1:1,000) overnight at 5°C. Membranes were then stir-washed three times for 10 min in phosphate-buffered saline (PBS). Subsequently, goat anti-mouse IgG-biotin secondary antibodies (1:10,000; Sigma-Aldrich) for 1 h at 37°C. ExtrAvidin-Alkaline Phosphatase (0.15 µg/ml; Sigma-Aldrich) with BCIP/NBT solution (Roche Diagnostics, Basel, Switzerland) was used to visualize the membranes. Western blot assays were conducted in triplicate and analyzed using densitometry (Molecular Imager Gel Doc and ChemiDoc systems) using Quantity One.
Observation of morphological changes indicating apoptosis. A549 cells were exposed to an 1.85 mM solution of 7-HC in ethanol or 3% ethanol for 6, 12 or 24 h with three replicates. Phase contrast images were captured using an Eclipse TS100 inverted microscope and a DXM1200c camera (Nikon Corporation, Tokyo, Japan) at a magnification of x400.

Calcium influx measurement. In order to determine calcium influx, 3x10^5 A549 cells were exposed in three replicates to an ethanolic solution of 7-HC (0.9 or 1.85 mM 7-HC) for 3, 6 and 12 h (data for 12 h not shown as the results were not significantly different). Cells were loaded for 40 min at 37°C with 4 µM Fura-2 AM. The cells were subsequently centrifuged at 300 x g for 5 min in 5 ml PBS. The pellet (100 µl) was immediately added to a heated cuvette (37°C) containing 2.5 ml PBS, which was constantly stirred with a magnetic bar. Ionomycin was used as positive control. Next, 6 mM EGTA was used to chelate the calcium. The fluorescence was detected at 488 nm using an optical filter (Andover Corporation, Salem, NH, USA), alternately exciting Fura-2 AM at 340/380 nm using a monochromator purchased from Photon Technology International (PTI; Monmouth Junction, NJ, USA). Data were acquired and digitized at 0.83 Hz using the PTI interface.

Single-cell microinjection. Cell microinjection (25) was performed using the Nikon Eclipse TS100 inverted microscope (Nikon Corporation, Tokyo, Japan) equipped with a programmable IM-300 microinjector and an MHW-3 hydraulic micromanipulator (Narishige International, Ltd., London, UK). Microinjection needles were crafted using borosilicate glass capillaries using a P-87 device (Sutter Instrument Co., Novato, CA, USA). Microinjection needles were loaded using Eppendorf microloaders (Eppendorf AG, Hamburg, Germany). Microinjection time and pressure parameters were determined using 0.1% dextran-FITC (3,000 MW) microinjection solution. The optimal injection time was determined as being between 200 and 400 msec, while the optimal microinjection pressure was 6.5 psi. In order to determine the basal activity of C-3, the specific substrate Z-DEVD-R110 was microinjected at a concentration of 1.3 mg/ml into single cells. Images were acquired using a DXM-1200C camera (Nikon Corporation).

For each assay, A549 cells were incubated for 3, 6, 12, 18 and 24 h with a 1.85 mM solution of 7-HC in ethanol or 3% ethanol (data for 18 h not shown as the results were not significantly different). Then, culture medium was withdrawn from the Petri dish and the cells were washed twice with 1 ml PBS. Finally, the cells were resuspended in 1 ml PBS and the microinjection of Z-DEVD-R110 into single cells was performed.

Image analysis. Prior to microinjection, images were captured at x400 magnification in phase contrast and green fluorescence (520 nm) to act as the negative control. Following the microinjection of the substrate, images were captured using a red filter at 615 nm. Immediately after this, fluorescence images were captured every 20 sec for 10 min. This method was standardized by determining the fluorescence intensity changes in each image. Digital images were obtained using NIS-Elements AR software, version 3 (Nikon Corporation), which was calibrated for use with a x40 lens. The C-3 activation dynamic was then analyzed in the various cell exposure groups.

Statistical analysis. Plots were generated and statistical analysis was performed using SigmaPlot for Windows, version 11.0 and SigmaStat, version 3.5 (Systat Software, Inc., San Jose, CA, USA). Analysis of variance tests were performed, and if a statistically significant difference was identified to isolate the group or groups that differ from the others then a multiple comparison versus control group (Dunnett's method) test was used. P<0.05 was considered to indicate a statistically significant result.

Results

Treatment with 7-HC reduces cell viability and increases C-3 activity in a time-dependent manner. A549 cells were incubated with 7-HC and MTT assays were performed to determine the cell viability. A 10% reduction in cell viability was observed following a 3-h exposure to 1.85 mM 7-HC; the cell viability further decreased by 30% after 12 h and ~40% after 24 h (data not shown).

The concentration-response of C-3 to 7-HC was obtained using endpoint colorimetric assays of the cell lysates. A statistically significant increase (P=0.009, Dunnett's method) in enzymatic activity (65%) was observed compared with the control group when the cells were incubated with 1.85 mM 7-HC for 24 h. The time course of treatment with 1.85 mM 7-HC for 24 h.
7-HC was evaluated, with measurements taken after 6, 12 and 24 h of exposure. The cells exposed to 1.85 mM 7-HC for 24 h exhibited a statistically significant difference in C-3 activity compared with the control (P<0.05, Dunnett’s method; Fig. 1).

7-HC increases the cleavage of procaspase-3 to C-3 in a time-dependent manner. After 24 h of exposure to various concentrations of 7-HC, lysates were obtained and subjected to gel electrophoresis in denaturing conditions. Subsequently, the levels of procaspase-3, C-3 and PARP were evaluated using western blot analysis. Bands for procaspase-3 and cleavage product C-3 were immunodetected in the cells that were treated with 0.92 and 1.85 mM 7-HC, but C-3 bands were not detected for the control (ethanol-treated) cells (Fig. 2A).

Treatment with 1.85 mM 7-HC did not induce the conversion of procaspase-3 into C-3 until the cells had been subjected to 24 h of exposure (Fig. 2B). Furthermore, the cells exposed to 1.85 mM 7-HC exhibited the characteristic activity of C-3 in the cleavage of PARP (Fig. 2C).

Furthermore, only 12 h of exposure to 1.85 mM 7-HC induced characteristic apoptotic changes in the cells, such as blebbing and shrinking, which were not observed in the control or RPMI-1640 (untreated) cells (Fig. 3).

7-HC exposure increases calcium conductance in A549 cells. The effects of 7-HC on calcium conductance in A549 cells were investigated. It was observed that a 3-h exposure to 0.9 mM 7-HC significantly increased calcium conductance by 17%, while exposure to 1.85 mM 7-HC for the same time period increased conductance by 27% (P<0.05) compared with that in the control group (Fig. 4A). Similarly, a 6-h exposure to 0.9 mM 7-HC increased conductance by 12%, while exposure to 1.85 mM 7-HC for the same time period increased conductance by 27% (P<0.05) compared with that in the control group (Fig. 4B).

7-HC exposure increases the activity of caspase-3 in single cells. Finally, single-cell microinjection assays were performed on cells that had been exposed to ethanol or 1.85 mM 7-HC for 3, 6, 12, 18 and 24 h and time course curves were prepared. The process was documented by capturing digital images every 5 sec over a 10-min period (Fig. 5A and B). Following the analysis of similar areas in each cell by measuring the intensity/pixel ratio using green fluorescence, the mean values were plotted (Fig. 5C). In each curve a phase of exponential increase was evident, followed by a plateau and an exponential phase of fluorescence reduction. Comparisons of the initial velocities through linear regression indicated that the real regression corresponds to 7-HC (slope >0), while the control had no slope >0. Thus, the results indicated the presence of typical first order enzymatic kinetics corresponding to C-3.

Discussion
In a previous study, it was demonstrated using flow cytometry that the exposure of A427 human lung adenocarcinoma cells to 0.98 mM 7-HC for 4-6 h, produced an 83% increase of Annexin-V-positive cells (12). In the present study, the inductive effect of 7-HC on C-3 activity in cellular lysates was demonstrated to occur in a concentration-dependent manner, and the optimal exposure time to obtain the maximum enzymatic activity was identified. Furthermore, the results of western blot analysis demonstrated the expression of procaspase-3 in the cells and its conversion into C-3 in a concentration- and time-dependent manner, in addition to the proteolytic cleavage of PARP by C-3, as described by Yang et al (13). Morphological changes associated with apoptosis were identified, such as blebbing and shrinking, comparable to the apoptotic bodies reported by Chuang et al (14) and Elinos-Báez et al (26). Chuang et al (14) reported a significant increase in calcium flux in HeLa cells treated for 24 h with 25-100 µM coumarin, using flow cytometry. Through fluorescence spectrometry, in the present study this effect was detected at a higher (millimolar) concentrations of 7-HC in cells exposed for 3 h. Furthermore, in the present study, experiments were conducted to determine how rapidly the exposure of A549 cells to 7-HC induced the activation of...
C‑3. To the best of our knowledge, single-cell microinjection has not previously been employed by other researchers in this type of study. The results indicate that 7-HC rapidly induced C-3 activation. The concentration that induced this rapid C-3 activation effect (1.85 mM) decreased cell viability by only 10% after 3 h of exposure.
The majority of previous studies have employed a maximum simple coumarin concentration of 100 µM and reported the reduction of viability at 24 or 48 h (10-17). However, it was not clear whether this rapid C-3 activation effect was induced by the binding of 7-HC with particular intracellular ligands. Zlabinger et al (27) demonstrated that in human monocytes, coumarin binding sites appeared to be present in relatively high numbers (7.5x10⁹/cell); however, their affinity was low (Kₐ~2x10⁻⁸ M⁻¹). Furthermore, inhibition experiments performed with 7-HC revealed that an ~4-fold molar concentration of 7-HC was necessary to induce a 50% displacement of coumarin from its binding site (27). It may be hypothesized that the C-3 activation effect, observed at higher concentrations compared with those previously reported, may be due to A549 cells possessing these binding sites.

Cytotoxic and cytostatic activity, in addition to the mechanisms by which these effects are produced, have been reported for a number of naturally occurring coumarins,
such as esculetin (11,13) and osthole (16,18), in addition to synthetic coumarins such as quercetin (17). However, the majority of these coumarins have not been subjected to testing beyond the pre-clinical phase, in contrast with the coumarins whose effects and pharmacokinetic properties in humans are widely known. The prompt conversion of coumarin into 7-HC, which has displayed the most relevant activity, as well as its rarity among patients (7) is well documented. In 1994, Marshall et al (28) reported the testing of 7-HC in a phase I trial in which patients who received daily dosages of between 1,000 and 7,000 mg presented few collateral effects. It has also been reported that 7-HC is not transported by multidrug resistance-associated proteins (4-7,29). As 7-HC has been previously employed in a number of phase II clinical studies, and has already been designated an Orphan drug by the US FDA, there is a possibility of successfully conducting further studies using 7-HC combined with conventional therapy as a lung cancer treatment.

Acknowledgements

This study constitutes a partial fulfillment of the Graduate Program in Biological Sciences of the National Autonomous University of México. The authors thank Hiram Molina Espinosa for critically reading the final version of the manuscript and making valuable suggestions. Grants were obtained from the National Science and Technology Council (no. 98729) and the Research and Technological Innovation Support Program from the National University of Mexico (no. IN216812).

References

1. U.S. National Cancer Institute: Surveillance, Epidemiology, and End Results Program. SEER Stat Fact Sheets: Lung and Bronchus Cancer. http://seer.cancer.gov/statfacts/html/lungb. html. Accessed April 14, 2015.
2. U.S. National Cancer Institute: Targeted Cancer Therapies. http://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet. Accessed April 12, 2015.
3. U.S. Food and Drug Administration (FDA): Search Orphan Drug Designations and Approvals. http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm. Accessed April 14, 2015.
4. Jain PK: Coumarin: Chemical and pharmacological profile. J App Pharm Sci 2: 236-240, 2012.
5. Casley-Smith JR and Casley-Smith JR: The pathophysiology of lymphedema and the action of benzo-pyrones in reducing it. Lymphology 21: 190-194, 1988.
6. Thorne R, Lynch G and Sechan MV: Cimetidine and coumarin therapy of melanoma. Lancet 2: 328, 1982.
7. Cox D, O’Kennedy R and Thorne R: The rarity of liver toxicity in patients treated with coumarin (1,2-benzopyrone). Hum Toxicol 8: 501-506, 1989.
8. Thorne R, Daly L, Lynch G, Browne H, Tanner A, Keane F, O’Loughlin S, Corrigan T, Daly P and Edwards G: Irish Melanoma Group: Prevention of early recurrence of high risk malignant melanoma by coumarin. Eur J Surg Oncol 15: 431-435, 1989.
9. Dexeus FH, Logothetis CJ, Sellas A, Fitz K, Amato R, Reuben JM and Dozier N: Phase II study of coumarin and cimetidine in patients with metastatic renal cell carcinoma. J Clin Oncol 8: 325-329, 1990.
10. Mohler Jl, Gamella LG, Crawford D, Glode LM, Zippe CD, Fair WR and Marshal: ME: Phase II evaluation of coumarin (1,2-benzopyrone) in metastatic prostatic carcinoma. Prostate 20: 123-131, 1992.
11. Chu CY, Tsai YY, Wang CJ, Lin WL and Tseng TH: Induction of apoptosis by esculetin in human leukemia cells. Eur J Pharmacol 416: 25-32, 2001.
12. López-González JS, Prado-García H, Aguilar-Cazares D, Molina-Guárneros JA, Morales-Fuentes J and Mandoki JJ: Apoptosis and cell cycle disturbances induced by coumarin and 7-hydroxycoumarin on human lung carcinoma cell lines. Lung Cancer 43: 275-283, 2004.
13. Yang YJ, Della-Fera MA and Baile CA: Esculetin induces mitochondria-mediated apoptosis in 3T3-L1 adipocytes. Apoptosis 11: 1371-1378, 2006.
14. Chuang YJ, Huang YF, Lu HF, Ho HC, Yang JS, Li TM, Chang NW and Chung JG: Coumarin induces cell cycle arrest and apoptosis in human cervical cancer HeLa cells through a mitochondria- and caspase-3 dependent mechanism and NF-kappB down-regulation. In vivo 21: 1003-1009, 2007.
15. Alvarez-Delgado C, Reyes-Chilpa R, Estrada Muñiz E, Mendoza-Rodríguez A, Quintero-Ruiz A, Solano J and Cebón MA: Coumarin A/AA induces apoptosis-like cell death in HeLa cells mediated by the release of apoptosis-inducing factor. J Biochem Mol Toxicol 23: 263-272, 2009.
16. Zhang L, Jiang G, Yao F, He Y, Liang G, Zhang Y, Hu B, Wu Y, Li Y and Liu H: Growth inhibition and apoptosis induced by osthole, a natural coumarin, in hepatocellular carcinoma. PLoS One 7: e37865, 2012.
17. Zheng SY, Li Y, Jiang D, Zhao J and Ge JF: Anticancer effect and apoptosis induction by quercetin in the cervical human cancer line A-S49. Mol Med Rep 5: 822-826, 2012.
18. Shokohinia Y, Hosseinizadeh L, Alipour M, Mostafaie A and Mohammadi-Mollah HG: Comparative evaluation of cytotoxic and apoptogenic effects of several coumarins on human cancer cell lines: Osthole induces apoptosis in p53-deficient H1299 cells. Adv Pharmacol Sci 2014: 847574, 2014.
19. Finn G, Creaven B and Egan D: Modulation of mitogen-activated protein kinases by 6-nitro-7-hydroxycoumarin mediated apoptosis in renal carcinoma cells. Eur J Pharmacol 481: 159-167, 2003.
20. Musa MA, Badisa VL, Latinwo LM, Patterson TA and Owens MA: Coumarin-based benzopyrone derivatives induced apoptosis in human lung (A549) cancer cells. Anticancer Res 32: 4271-4276, 2012.
21. Goel A, Prasad AK, Parmar VS, Ghosh B and Saini N: Apoptogenic effect of 7,8-diacetoxy-4-methylcoumarin and 7,8-diaetoxy-4-methylthiocoumarin in human adenocarcinoma cell line: Role of NF-kappa B, Akt, ROS and MAP kinase pathway. Chem Biol Interact 179: 363-374, 2009.
22. Goel A, Chhabra R, Ahmad S, Prasad AK, Parmar VS, Ghosh B and Saini N: DMTC regulates cytoskeletal reorganization and cell motility in human adenocarcinoma cell line: An integrated proteomics and transcriptomics approach. Cell Death Dis 3: e402, 2012.
23. Schilling WH, Crampton RF and Longland RC: Metabolism of coumarin in man. Nature 221: 664-665, 1969.
24. Mossman T: Rapid colorimetric assay for cellular growth and survival: Applications to proliferation and cytotoxicity assay. J Immunol Methods 65: 55-63, 1983.
25. Zhang Y: Single-cell microinjection technologies. In: Single-cell Analysis: Methods and Protocols. Lindström S and Andersson-Svahn H (eds.). Humana Press, Heidelberg, pp69-176, 2012.
26. Elimos-Báez CM, León F and Santos E: Effects of coumarin and 7-OH-coumarin on bel-2 & bax expression in two human lung carcinoma cell lines in vitro. Cell Biol Int 29: 703-708, 2005.
27. Zlabinger GJ, Nöhammer C, Böhmig GA and Menzel JE: Mode of action of coumarin in immune cells. J Cancer Res Clin Oncol 120 (Suppl): S17-S18, 1994.
28. Marshall ME, Mohler JL, Edmonds K, Williams B, Butler K, Ryles M, Weiss L, Urban D, Bueschen A and Markiewicz M: An updated review of the clinical development of coumarin (1,2-benzopyrone) and 7-hydroxycoumarin. J Cancer Res Clin Oncol 120 (Suppl): S39-S42, 1994.
29. Wittgen HG, van den Heuvel JJ, van den Bruck PH, Sissalo S, Groothuis GM, de Graaf IA, Koenderink JB and Russel FG: Transport of the coumarin metabolite 7-hydroxycoumarin glucuronide is mediated via multidrug resistance-associated proteins 3 and 4. Drug Metab Dispos 40: 1076-1079, 2012.